Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
Access event page
The ESC Working Group on Cardiovascular Pharmacotherapy presents an engaging and interactive course to improve the professional knowledge and skills on cardiovascular pharmacotherapy in older patients.
In Europe and the Western World in particular, the proportion of older people is dramatically increasing, which is predicted to add tremendous extra pressure to the strained healthcare systems.
Cardiovascular drugs are among the most prevalent drugs administered to older people. In particular diuretics, antihypertensives, NOACs, antiarrhythmics, lipid-lowering and glucose-lowering drugs. All these drug classes can lead to increased frailty and should in particular not be prescribed on a one-size-fits-all-basis to older people, and polypharmacy should be countered.
Our goal is for all participants to leave the meeting with the improved competence and confidence to deliver better, personalised therapy to older people, which in turn will have a positive impact on services and patient outcomes.
The programme is subject to change.
Ageing and challenges to cardiovascular pharmacotherapy. The added challenge of COVID-19
Drug metabolism in older people
The problem of hypo- and hyperkalemia in older people
How to select anti-hypertensive agents in older patients
Problems with anti-hypertensive therapy in the elderly: case discussion
Therapeutic decisions in the elderly
LIPID LOWERING DRUGS
Lipid-lowering agent selection in the elderly
GLUCOSE LOWERING DRUGS
Tight glycemic control, pros and cons [Debate]
DOACS IN AF STROKE PREVENTION
The use of DOACs in older individuals
Guidelines & effects of the pandemic: cases
PHARMACOTHERAPY AND INTERVENTION IN OLDER WOMEN
Challenges to cardiovascular pharmacotherapy
Challenges to cardiovascular intervention
Problems with polypharmacy in older people
COVID-19 TREATMENTS IN THE ELDERLY
Are we shooting in the dark?
Reduction of cardiovascular disease burden by pharmacotherapy is a multistep approach, which requires to:
Older patients with cardiovascular disease are often found to be undertreated. There are many reasons for this, including polypharmacy, fear of side effects, co-morbidities, frailty and sparse trial evidence of drug efficacy in the elderly. Strategies leading to the rational implementation of pharmacological therapies are therefore necessary in the subgroup of older patients with cardiovascular disease.
The specific aim of the course is to improve the practicing physician’s competence and confidence to deliver better, safer, personalized therapy for older people, which should, in turn, have a positive impact on patient outcomes and quality of life.
Free for everyone.
An application has been made to the UEMS EACCME® for CME accreditation of this event.
This course is organised by the ESC Working Group on Cardiovascular Pharmacotherapy.Not a member yet? Join today
This course is dedicated to physicians dealing with hospital admissions, ward and outpatient consultations.
The first course on Pharmacotherapy in Older People took place in October 2019 in London, with over 40 participants.
Access the resources
For any questions, please contact us on email@example.com
European Society of Cardiology
European Heart HouseLes Templiers2035 Route des CollesCS 80179 Biot
06903, Sophia Antipolis, FR
This programme is supported by Daiichi Sankyo and Novartis Pharma AG in the form of an educational grant. The scientific programme has not been influenced in any way by its sponsor.
Our mission: To reduce the burden of cardiovascular disease.
© 2020 European Society of Cardiology. All rights reserved.